Replying for Fuma - making this thread easier to find. Someone wiser than me said the following:"Dr Watson said: "Clostridium difficile costs Europe £1billion a year in healthcare costs. You could view that as saved money or saved beds.""....http://www.dailymail.co.uk/health/article-510758/Jab-beat-C-...I think that is a hugely inflated number, and I dont believe there is a vaccine on the horizon that will be heavily used in the US within the next 5-8 years.... however, I do believe that the actual amount spent on antibiotic treatment warrants a market value higher than OPTR is fetching.what OPTR, or any other CDiff mab maker does NOT need is this: some ICU journal making recommendations against their use the way that the American Diabetes Association recommended against using new agents like Byetta. If an ICU journal puts out a strong rec for it, and an ICU has good results after using it, the medical/surgical floors will soon follow. Its going to be awhile, but just a year ago consider what JPG wrote:"We haven't had an ICU death in over 6 months since we started giving high dose vanco early and enterally. " (http://boards.fool.com/Message.asp?mid=26129179)... now, there are numerous reported cases of vanco resistant cdiff.
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ra